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T cell acute lymphoblastic leukemia (T-
ALL) develops in a multistep process
whereby thymic progenitor cells gradually
accumulate genetic and epigenetic chang-
es, eventually leading to fully transformed
immature lymphoblasts. Aberrant activa-
tion of transcription factor oncogenes is
considered a core component of the
oncogenic program that drives malignant
T cell transformation. For example, the
TAL1 (SCL) and LYL1 basic Helix-Loop-
Helix (bHLH) transcription factors, as well
as the LIM domain–only proteins LMO1
or LMO2, are activated by chromosomal
translocations or interstitial deletions in a
large fraction of primary T-ALLs. Nota-
bly, these leukemias often present with
activating NOTCH1 mutations, suggesting
that enhanced NOTCH signaling and
aberrant TAL1, LYL1, LMO1, and/or
LMO2 expression are collaborative events
in the multistep pathogenesis of T-ALL
[1,2]. Recent experimental evidence un-
covered the existence of long-lived pre-
leukemic stem cells (pre-LSCs) with self-
renewal properties, allowing clonal expan-
sion and subsequent acquisition of onco-
genic mutations leading to cancer [3,4].
For example, DNMT3A mutant pre-LSCs
were shown to survive chemotherapy and
represent a reservoir for leukemic progres-
sion and hematological relapse in acute
myeloid leukemia (AML) [5,6]. Although
the concept of pre-leukemic stem cells has
been previously proposed in the context of
T-ALL [7], the actual molecular mecha-
nisms by which T cell-specific oncogenes
regulate pre-LSC activity of thymic pre-
cursors remains largely unexplored. Nota-
bly, these mechanistic insights could pro-
vide valuable input for the development of
novel therapeutic strategies that can effec-
tively eradicate quiescent and therapy-
resistant clones [4,6,7].
Pre-leukemic Stem Cells: It’s All
in the DN3
In this issue of PLOS Genetics, Gerby
et al. [8] used the SCLtgLMO1tg trans-
genic mouse model [9] to investigate the
molecular pathways that mediate the
transition of normal thymic precursors
into pre-LSCs. Interestingly, combined
SCL and LMO1 overexpression was
sufficient to reprogram double negative 3
(DN3) T cell precursors with a finite
lifespan into pre-LSCs with self-renewal
activity and retained differentiation capac-
ity (Fig. 1). Moreover, transcriptome anal-
ysis revealed that this transition towards
pre-LSC was accompanied by a marked
up-regulation of a stem cell signature,
including Hhex, Nfe2, and Lyl1. Notably,
Gerby et al. [8] also used LYL1tgLMO1tg
transgenic mice to show that combined
LYL1 and LMO1 overexpression results in
similar reprogramming activities, as ob-
served for SCL-LMO1. These results
confirm recent work from McCormack
and colleagues showing Lyl1 as an essen-
tial, but not sufficient, factor to reprogram
Lmo2 overexpressing DN3 cells into pre-
LSCs [10]. All together, these data
convincingly show that combined activa-
tion of SCL or LYL1 together with LMO1
or LMO2 can drive oncogenic reprogram-
ming of DN3 thymic precursors into self-
renewing pre-LSCs.
NOTCHing up Pre-leukemic
Stem Cells
High physiological levels of Notch1
signaling drive irreversible T-lineage com-
mitment at the DN3 stage of T cell
differentiation. Therefore, enhanced
Notch1 activity could be critically involved
in the reprogramming capacity of SCL-
LMO1. Strikingly, Gerby and colleagues
[8] showed that the self-renewal capacity
of SCLtgLMO1tg DN3 cells was complete-
ly abrogated upon ablation of Notch1
activity by c-secretase inhibitor treatment
(Fig. 1). For the first time, these results
unambiguously show that high physiolog-
ical levels of Notch1 are critically required
for SCL-LMO1–driven reprogramming of
DN3 thymocytes into self-renewing pre-
LSCs. Conversely, Gerby et al. [8] showed
that supraphysiological levels of Notch1
significantly expanded the pool of pre-
LSC; enhanced their engraftment and
rendered them independent of the thymic
microenvironment (Fig. 1). Remarkably,
Notch1 activation by itself was not suffi-
cient to trigger reprogramming activity,
suggesting that the Notch1 oncogene is
devoid of intrinsic self-renewal capacity,
but confers a proliferative advantage to
SCL-LMO1–primed pre-LSCs (Fig. 1). If
the molecular mechanisms, as described
above, turn out to be conserved in the
human setting, inhibition of NOTCH
signaling by c-secretase inhibitors, small
molecule inhibitors or antibodies targeting
specific Notch receptors, could serve as an
attractive approach to effectively target
pre-LSCs for the treatment of human T-
ALL. Most notably, in that scenario,
eradication of the quiescent and chemo-
resistant pre-LSCs by inactivation of
NOTCH signaling might be applicable
for a large fraction of primary human T-
ALL patients, irrespective of their
NOTCH1 mutational status at diagnosis.
Furthermore, Gerby et al. [8] also showed
that Myc acts as a critical mediator of pre-
LSC activity downstream of Notch1,
suggesting that combined NOTCH/
MYC inhibition by c-secretase and BET-
bromodomain inhibitors [11] could fur-
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ther potentiate therapeutic targeting of the
pre-LSC population in the context of
human T-ALL (Fig. 1).
Thymocyte Self-Renewal: In
Which E Proteins Meet LMOs
From a mechanistic point of view, it has
been previously postulated that the onco-
genic potential of SCL and LYL1 is
mediated by inhibition of E proteins
[12]. Indeed, SCL and LYL1 can hetero-
dimerise with E2A or HEB and form
inactive transcriptional complexes that
drive repression of E protein target genes,
including critical regulators of T cell
differentiation (Ptcra, Il7r, and Rag2)
[12]. Alternatively, SCL and LYL1 can
directly interact with LMO1 or LMO2
and recruit other co-activators to form
active multiprotein transcriptional
complexes that drive specific target gene
expression [13]. Up until now, no concrete
proof existed for whether the sequestration
of E proteins is truly the major cause of
SCL-driven leukemia development. Here,
the authors generated a transgenic mouse
model expressing a mutant form of SCL
(SCLm13) that is defective in LMO1/2
binding, but still inhibits E proteins
through heterodimerization [8]. Strikingly,
the authors observed a strong delay in
leukemia onset and a reduced tumor
penetrance in the SCLm13tgLMO1tg ver-
sus SCLtgLMO1tg transgenic mice, sug-
gesting that E protein inhibition is not the
main oncogenic property of SCL in this
model of murine T cell leukemogenesis.
Furthermore, combined SCLm13 and
LMO1 overexpression was unable to
reprogram DN3 cells into pre-LSCs. All
together, these data suggest that the
SCL-LMO1 interaction is essential for
the generation of pre-LSCs through reac-
tivation of stem cell genes (Hhex, Lyl1)
and serves as a critical mediator of
malignant T cell transformation. Given
this, targeting the SCL-LMO1/2 or
LYL1-LMO1/2 [10] protein–protein in-
teraction by small molecule inhibitors
might represent an elegant new therapeu-
tic approach to constrain self-renewing
capacity of both leukemic and pre-leuke-
mic cancer stem cells in T-ALL.
In conclusion, this study [8] nicely
illustrates how cooperative transcription
factor oncogenes can reprogram normal T
cells into pre-LSCs during the earliest
steps of malignant T cell transformation.
Although these results provide novel
insights in the multistep pathogenesis of
T-ALL and have important therapeutic
implications, it remains to be established
Fig. 1. Hypothetical model describing pre-leukemic stem cells formation and T-ALL development in SCLtgLMO1tg mice. Schematic
presentation of T-ALL progression based on experimental evidence presented by Gerby et al. Upper part represents the progression of T-ALL
development in a thymus initiated by the formation of a pre-leukemic stem cell population, allowing clonal expansion and subsequent acquisition of
oncogenic mutations, eventually leading to a mono/oligoclonal tumor. The lower part depicts results obtained after transplantation of thymocytes at
different stages of tumor development and the effects of altering NOTCH1 signaling or its downstream component MYC on their repopulating
capacity.
doi:10.1371/journal.pgen.1004881.g001
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whether gain of pre-leukemic self-renewal
capacity is a true obligatory trait for
human T-ALL development. Moreover, it
would be interesting to know if other T-
ALL–specific transcription factor onco-
genes, including TLX1, TLX3, or HOXA,
also possess the intrinsic capacity to induce
self-renewal in T cell progenitors [7]. In
regard to this notion, it is currently unclear
if the results presented in this study are
broadly relevant for the majority of primary
human T-ALLs or if they specifically apply
to a particular molecular genetic subtype of
this disease. For example, early immature
T-ALLs show high expression levels of
SCL, LYL1, LMO1, and LMO2 as a
reflection of their maturation arrest at the
early double negative stages of T cell
differentiation [14]. In contrast, chromo-
somal translocations or small genomic
deletions targeting SCL, LYL1, and/or
LMO2, are exclusively present in primary
human T-ALLs with a late cortical tumor
phenotype [1]. Therefore, the functional
role of SCL, LYL1, and/or LMO2 in
regulating self-renewal capacity might be
influenced by the immunophenotypic back-
ground of the different molecular-genetic
subtypes of human T-ALL, a notion that
could be tested using transgenic models
that overexpress the specific members of
this bHLH transcription complex at later
stages during T cell development.
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